Ethosuximide NDC 59762-2350

NDC codes

FDA NDC Directory

Product NDC (as listed)59762-2350Labeler and product segments. Claims need a package NDC.

Product NDC at billing width59762-2350Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
59762-2350-6	59762235006	1 BOTTLE, PLASTIC in 1 CARTON (59762-2350-6) / 474 mL in 1 BOTTLE, PLASTICMarketed from Feb 21, 2020
59762-2350-7	59762235007	1 BOTTLE, PLASTIC in 1 CARTON (59762-2350-7) / 474 mL in 1 BOTTLE, PLASTICMarketed from Jul 1, 2022

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ethosuximide
Generic name (nonproprietary): ethosuximide
Active ingredients: Ethosuximide — 250 mg/5mL
Dosage form: Solution
Route: Oral
Labeler: Mylan Pharmaceuticals Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 080258
Marketing start: Feb 21, 2020
Listing expires: Dec 31, 2027
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 59762-2350_04f63742-92af-4b78-a7a6-f9f2f1c269e7SPL ID 04f63742-92af-4b78-a7a6-f9f2f1c269e7SPL set ID 19c924c2-f558-4c78-9277-2d7e0df2f505RxCUI 251322UNII 5SEH9X1D1D
Pharmacologic class: Anti-epileptic Agent

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N459762235006 followed by a unit qualifier and the quantity

Package 59762-2350-06. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 24, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Ethosuximide is indicated for the control of absence (petit mal) epilepsy.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 080258

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 080258
Product	Strength	Form · route	Labeler	Product NDC
Zarontinethosuximide	Ethosuximide 250 mg/5mL	SolutionOral	Parke-Davis Div of Pfizer Inc	0071-2418